GLP1R and metabolic dysfunction-associated steatotic liver disease: Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), exhibits beneficial effects on weight loss, cardiovascular function, and NAFLD in addition to its glucose-lowering effect, especially in patients with obesity (Drucker, 2018; Muller et al., 2019).